|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG008886245 |
003 |
DE-627 |
005 |
20230425173059.0 |
007 |
cr uuu---uuuuu |
008 |
230113s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG008886245
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-000202-22-DE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)64407564MMY3002
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a A Randomized Study Comparing Talquetamab in Combination WithDaratumumab and Pomalidomide or Talquetamab in Combination WithDaratumumab Versus Daratumumab, Pomalidomide and Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
|b A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy - MonumenTAL-3
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 09-06-2022, Last updated: 2023-01-13
|
650 |
|
4 |
|a Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 09. Jan.
|
773 |
1 |
8 |
|g year:2023
|g day:09
|g month:01
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000202-22
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 09
|c 01
|